neuropeptide dihexa Peptide Therapy Dihexa Peptide Therapy: Brain &

For a more detailed description and lab analysis, please see the sections below

Key Research Points at a Glance A 15-amino-acid fragment of a gastric-juice-derived protective protein, first characterised in the early 1990s Primary research mechanisms: angiogenesis (VEGF pathway) and gastric/gut-lining signalling Secondary mechanisms under study: growth factor modulation (EGF, FGF) and nitric oxide system interaction Frequently co-researched with TB-500 despite acting through an unrelated mechanism The large majority of published research is pre-clinical (in-vitro and animal-model), not human clinical data Notably stable across a wider pH/temperature range than many comparable research peptides What Is BPC-157

This gives it anxiolytic properties with a significantly lower risk of dependence or sedation

Total Peptide: 10,000mcg Total Liquid: 4mL (which equals 400 units) Calculation: 10,000mcg 400 units = 25mcg of Tesamorelin per 1 unit on the syringe

Cellular senescence is a primary driver of biological aging

GLP1: glucagon- like peptide1) Serotonin (5- hydroxytryptamine or 5HT) receptor modulation The nonselective serotonergic antiobesity drugs fenfluramine and dexfenfluramine have been associated with severe side effects like valvular heart disease and pulmonary hypertension